

## DAFTAR PUSTAKA

1. Nepogodiev D, Martin J, Biccard B, Makupe A, Bhangu A, Ademuyiwa A, et al. Global burden of postoperative death. *Lancet*. 2019; 393-401.
2. Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, et al. Mortality after surgery in Europe: a 7 day cohort study. *Lancet*. 2012; 380: 1059–1065.
3. Lerman BJ, Popat RA, Assimes TL, Heidenreich P., Wren SM. Association of left ventricular ejection fraction and symptoms with mortality after elective noncardiac surgery among patients with Heart Failure. *Jama*. 2019; 321: 572–579.
4. Yurttas T, Hidvegi R, and Filipovic M. Biomarker based preoperative risk stratification for patients undergoing non cardiac surgery. *J. Clinical medicine*. 2020; 9 (2): 22-45.
5. Duceppe E, Parlow J, Macdonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian cardiovascular society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. *J. Cardiol*. 2017; 33: 17–32.
6. Antman EM, Schactman M, McCabe CH, Fischer GA, Fung AY, Wybenga D, et al. Cardiac specific troponin I levels to predict the risk of mortality in patients with Acute Coronary Syndromes. *New England. J. Med*. 1996; 335: 1342–1349.
7. Weber M, Luchner A, Seeberger M, Mueller C, Liebetrau C, Schlitt A, et al. Incremental value of high-sensitive troponin T in addition to the revised cardiac

- index for peri-operative risk stratification in non-cardiac surgery. *Eur Heart J.* 2013; 34: 853–862.
8. Nagele P, Brown F, Gage BF, Gibson DW, Miller JP, Jaffe AS, et al. High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. *Am Heart J.* 2013; 166: 325–332.
  9. Tevaearai Stahel, Hendrik T.; Do, Peter D.; Klaus, Jeremias Bendicht; Gahl, Brigitta; Locca, Didier; Göber, Volkhard; Carrel, Thierry P. (2018). Clinical Relevance of Troponin T Profile Following Cardiac Surgery. *Frontiers in Cardiovascular Medicine*, 5, 182–.
  10. Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. *Targets and Therapy.* 2020; 13: 161–174.
  11. Chong WH, Yanoff LB, Andraca CE, Hai MT. Assessing the safety of glucose-lowering drugs – a new focus for the FDA. *The new England J. medicine.* 2020; 383 (13): 1199–1202.
  12. Arnott C, Li Q, Kang A, Neuen BL, Bompont S, Lam CS, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 Diabetes Mellitus. *J. American heart association.* 2020; 9 (3): 111-124.
  13. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death. *J. American heart association.* 2017; 6 (7): 34-41.

14. Lin Z, Lim SH, Chua SJ, Tai ES, Chan YH, Richards AM. High-sensitivity troponin T and long-term adverse cardiac events among patients presenting with suspected acute coronary syndrome in Singapore. *Singapore medical journal*. 2019; 60 (8): 418–426.
15. Chenevier GC, Bonnefoy CÉ, Charpentier S. SFBC SFC SFMU troponins workgroup. *Arch cardiovasc disease*. 2015; 108: 132–149.
16. Stark M, Kerndt CC, Sharma S. Troponin treasure island. *Stat pearls publishing*. 2023; 40: 34-46.
17. Kavsak PA, Walsh M, Srinathan S. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. *Clin Biochem* 2011; 44.
18. Botto F, Alonso CP, Chan MT. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. *J. Anesthesiology*. 2014; 120: 564.
19. Mol K, Hoeks SE, Mieghem N. Preoperative coronary angiography in vascular surgery patients with asymptomatic elevated high-sensitivity troponin T: a case series. *Br J. Anaesth*. 2019; 123: 565.
20. Zhao BC, Liu WF, Deng QW, Zhuang PP, Liu J, Li C, et al. Meta-analysis of preoperative high-sensitivity cardiac troponin measurement in non-cardiac surgical patients at risk of cardiovascular complications. *British J. Surgery*, 2020; 107 (2): 81–90.

21. Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. *PLOS One*. 2018; 13 (6): 301-333.
22. Robertson T, Beveridge G, Bromley C. Allostatic load as a predictor of all-cause and cause-specific mortality in the general population: evidence from the scottish health survey. *PLOS One*. 2017; 12 (8): 18-34.
23. Knott JD, Ola O, De ML, Akula A, Mehta RA, Dworak M, et al. Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction. *European heart journal*. 2022; 11 (7): 546–557.
24. Tsai, IT., Wang, CP., Lu, YC. et al. The burden of major adverse cardiac events in patients with coronary artery disease. *BMC Cardiovasc Disord* 17, 1 (2017). <https://doi.org/10.1186/s12872-016-0436-7>
25. Janikowski K, Morawiec R, Jegier B, Jaszewski R, Lelonek M. EuroSCORE II does not show better accuracy nor predictive power in comparison to original EuroSCORE: A single-centre study. *Kardiol Pol*. 2016; 74 (5): 469–500.
26. Kusuma DI, Jatmiko HD. Penilaian praoperasi bedah jantung preoperative assessment of cardiac surgery. *J. Anestesiologi Indonesia*. 2018; 10 (3): 175–187.
27. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. Euroscore II. 2012; 41(4): 734–745.

28. Farouk MA, Cheong XP, Dillon J, Nordin RB. Validation of euroSCORE II in patients undergoing *coronary artery bypass grafting* (CABG) surgery at the national heart institute. Kuala Lumpur. 2018; 7: 1–18.
29. Indrawijaya YYA, Suharjono S, Aminuddin M, Retnowati E, Rahman GM. Changes on Serum Troponin T Level before and after Taking Standard Therapy Medication in Heart Failure Patients. *Folia Medica Indones*. 2020;56 (1):4.
30. Bollen Pinto B, Ackland GL. Pathophysiological mechanisms underlying increased circulating cardiac troponin in noncardiac surgery: a narrative review. *Br J Anaesth*. 2024;132(4):653–66.
31. Horr S, Reed G, Menon V. Troponin elevation after noncardiac surgery: Significance and management. *Cleve Clin J Med*. 2015;82(9):595–602.
32. Zhao BC, Liu WF, Deng QW, Zhuang PP, Liu J, Li C, et al. Meta-analysis of preoperative high-sensitivity cardiac troponin measurement in non-cardiac surgical patients at risk of cardiovascular complications. *Br J Surg*. 2020;107(2): e81–90.
33. Bollen Pinto B, Ackland GL. Pathophysiological mechanisms underlying increased circulating cardiac troponin in noncardiac surgery: a narrative review. *Br J Anaesth*. 2024;132(4):653–66.
34. Noordzij PG, Van Geffen O, Dijkstra IM, Boerma D, Meinders AJ, Rettig TCD, et al. High-sensitive cardiac troponin T measurements in prediction of non-cardiac complications after major abdominal surgery. *Br J Anaesth* [Internet]. 2015;114(6): 909–18.
35. Sellers D, Srinivas C, Djaiani G. Cardiovascular complications after non-

- cardiac surgery. *Anaesthesia*. 2018;73:34–42.
36. Chew MS, Saugel B, Lurati-Buse G. Perioperative troponin surveillance in major noncardiac surgery: a narrative review. *Br J Anaesth* [Internet]. 2023;130(1):21–8.
  37. Gualandro DM, Puelacher C, LuratiBuse G, Lampart A, Strunz C, Cardozo FA, et al. Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery. *Am Heart J*. 2018;203: 67–73.
  38. Petricciuolo S, Delle Donne MG, Aimo A, Chella A, De Caterina R. Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. *Eur J Clin Invest*. 2021;51(4): 0–3.
  39. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, et al. Elevation in high-sensitivity troponin t in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. *Circ Hear Fail*. 2014;7(6): 953–9.
  40. Aimo A, Januzzi JL, Vergaro GGV, Ripoli A, Latini R, Masson S, et al. Prognostic value of high-sensitivity troponin T in chronic heart failure an individual patient data meta-analysis. *Circulation*. 2018;137(3): 286–97.
  41. Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: Insights from the RELAX-AHF study. *Eur J Heart Fail*. 2015;17(12):1262–70.
  42. D’Amato A, Severino P, Prosperi S, Mariani MV, Germanò R, De Prisco A, et

- al. The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum. *J Clin Med.* 2024;13(12): 1–15.
43. Ackland GL, Abbott TEF, Jones TF, Leuwer M, Pearse RM, Niebrzegowska E, et al. Early elevation in plasma high-sensitivity troponin T and morbidity after elective noncardiac surgery: prospective multicentre observational cohort study. *Br J Anaesth.* 2020;124(5): 535–43.
44. Zheng P, Wang X, Guo T, Gao W, Huang Q, Yang J, et al. Cardiac troponin as a prognosticator of mortality in patients with sepsis: A systematic review and meta-analysis. *Immunity, Inflamm Dis.* 2023;11(9): 1–13.
45. Landesberg G, Jaffe AS. “Paradox” of troponin elevations after non-cardiac surgery. *Br J Anaesth.* 2015;114(6): 863–5.



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR



Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
Contact Person: dr. Agusalm Bukhari, MMed, PhD, SpCK, TLP. 081241850858, 0411 5780103, Fax : 0411-581431

### REKOMENDASI PERSETUJUAN ETIK

Nomor : 744/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 17 September 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24080599	No Sponsor	
Peneliti Utama	dr. M. Ridha Zulfikar, MH	Sponsor	
Judul Peneliti	BIOMARKER TROPONIN-T PASIEN KARDIAK YANG MENJALANI OPERASI NON KARDIAK di RSUP dr. WAHIDIN SUDIROHUSODO MAKASSAR		
No Versi Protokol	1	Tanggal Versi	9 Agustus 2024
No Versi PSP	1	Tanggal Versi	9 Agustus 2024
Tempat Penelitian	RSUP dr. WAHIDIN SUDIROHUSODO MAKASSAR		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 17 September 2024 sampai 17 September 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

#### Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

**CURRICULUM VITE**

## 1. DATA PRIBADI

Nama Lengkap : dr. M. Ridha Zulfikar. MH  
 Tempat tanggal lahir : Rappang, 19 Maret 1991  
 Jenis Kelamin : Laki-laki  
 Kewarganegaraan : Warga Negara Indonesia  
 Agama : Islam  
 Alamat : Perumahan Dosen Unhas, Jalan Michael Faraday Blok EC  
 No. 10 Tamalanrea Makassar  
 Email : mridhazulfikarmh@gmail.com

## 2. RIWAYAT PENDIDIKAN

No	Jenjang Pendidikan	Institusi	Tahun	Tempat
1	SD	SD Negeri 2 Pancarijang	1997-2003	Sidrap
2	SMP	SMP Negeri 1 Pancarijang	2003-2006	Sidrap
3	SMA	SMA Negeri 2 Tinggimoncong	2006-2009	Gowa
4	S1 & Pofesi	FK Universitas Muhammadiyah Makassar	2009-2018	Makassar
5	PPDS	Departemen Ilmu Anestesi, Terapi Intensif dan Manajemen Nyeri FK Universitas	2021-2025	Makassar